No Data
No Data
Express News | BlackRock Inc's Long Position in H-Shares of WuXi AppTec Increases to 6.01% on Dec 23 From 4.72% - HKEX
Guosen: Continuously recommending Innovative Drugs and paying attention to investment opportunities in Medical Devices.
Currently, the Industry is undergoing significant supply-side structural reforms, and the collective procurement of Pharmaceuticals and Medical Devices is also nearing completion, with the expectation of entering a new growth cycle in 2025.
[Brokerage Focus] Citigroup raises WUXI APPTEC (02359) Target Price to 74 HKD, indicating that the sale of the ATU Business may alleviate U.S. concerns about its Gene Business.
Goldbug Financial News | Citigroup's Research Reports indicate that WUXI APPTEC (02359) will sell its ATU Business (cell and gene therapy CDMO services) to Altaris, which is expected to alleviate concerns in the USA regarding the company's gene business. Citigroup believes that given the limited time for Senate voting on the Biosecure Act during the Biden administration, geopolitical risks are expected to decrease by 2025. Citigroup anticipates that as Global pharmaceutical research and development investments continue to grow, the demand for pharmaceutical outsourcing services will remain strong. Especially in the field of cell and gene therapy, with the maturity of technology and the expansion of therapeutic applications, outsourcing services will continue to thrive.
WuXi AppTec's Sale of Advanced Therapies Unit Likely to Alleviate U.S. Concerns -- Market Talk
Announcement highlights | CHINA POWER's electricity sales volume increased by nearly 30% year-on-year in the first 11 months; WUXI APPTEC plans to sell its WuXi ATU Business in the USA and United Kingdom.
WUXI APPTEC plans to sell its WuXi ATU Business in the USA and United Kingdom; GF SEC's proprietary business can participate in carbon emission trading at legal trading venues within the territory.
WuXi AppTec's Unit to Sell Shareholding in U.S., UK Operating Entities for Cash Consideration